Advanced Search
Contact | Corporate | Help

Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

Sponsors:
  • Massachusetts General Hospital
  • Genentech
  • Beth Israel Deaconess Medical Center
  • Dana-Farber Cancer Institute
Phases:
  • Phase II
IndicationsAcronym:
  • Pancreatic Cancer
  • Adenocarcinoma of the Pancreas
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Bevacizumab
  • Drug: Erlotinib
  • Drug: Gemcitabine
Enrollment:
30

Additional information about NCT00366457.


SourceSolution © 2008-2012